Chhindwara, India — A central investigation team from the National Centre for Disease Control (NCDC) is actively examining the recent deaths and illnesses linked to a cough syrup in Madhya Pradesh’s Chhindwara district. This inquiry comes amidst mounting concerns, as similar incidents have been reported in Rajasthan, leading to a statewide suspension of specific syrup batches for testing.
The health crisis began with the death of a five-year-old boy in Sikar, Rajasthan, after consuming a cough syrup provided through the state’s free medicine initiative. Concurrently, a three-year-old child in Bharatpur fell critically ill after ingesting the same medication, prompting urgent action from local health authorities.
In Chhindwara, six children have reportedly succumbed to suspected kidney infections within the past month, with preliminary investigations indicating a connection to two similar types of cough syrups. In response, district administration has banned the distribution of Coldrif and Nextro-DS syrups to prevent further complications.
Health officials are analyzing multiple samples—including water and drug specimens—to rule out other infectious diseases, though the focus remains on the quality and safety of the cough syrup. The potential misuse of these medications has raised alarms, especially considering reports of children experiencing severe symptoms after administration.
In Rajasthan, health officials received complaints regarding two specific syrup batches that were associated with adverse reactions. The Rajasthan Medical Services Corporation Limited (RMSCL) has since halted the distribution of all affected units while launching a formal investigation. It was confirmed that more than 133,000 patients were administered the syrup prior to these alarming reports, highlighting the urgent nature of the situation.
The continued use of cough syrup designed for adults has spurred concerns about its suitability for young children, with all affected patients being under the age of four. Experts stress the importance of correct prescribing practices, particularly in public health schemes designed for vulnerable populations.
Meanwhile, local and state health officials are soliciting test results urgently to guide further action. The NCDC’s ongoing analyses aim to uncover the underlying issues while ensuring public safety, with all findings expected to be shared with appropriate state authorities.
Pulmonologists and pediatric specialists advise against the unsupervised use of over-the-counter cough medications for children, emphasizing the need for professional medical guidance before administering any drugs. Doctors are calling on parents to be vigilant and consult healthcare providers, particularly for children under five.
As investigations evolve, both central and state authorities are poised for decisive action based on the outcomes of laboratory tests and internal inquiries. For now, the distribution of implicated syrup batches remains suspended, and the effectiveness of quality control within public health frameworks is being scrutinized closely.